Tetrazoles

Global Losartan Market (2020 to 2026) - by Source, Form, Strength, Distribution Channel, Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021

The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.

Key Points: 
  • The Global Losartan Market is segmented based on source, form, strength, distribution channel, application, end-user, company and region.
  • To estimate and forecast the market size of the Global Losartan Market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast the Global Losartan Market based on source, form, strength, distribution channel, application, end-user, company and regional distribution.
  • To identify key sustainable strategies adopted by market players in the Global Losartan Market.

Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Friday, May 21, 2021

b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

Key Points: 
  • b'DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the Jefferies Virtual Healthcare Conference on Thursday, June 3, at 2:30 p.m. ET.\nNabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA\xc2\xae (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP).
  • Nabriva Therapeutics is also developing CONTEPO\xe2\x84\xa2 (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO\xc2\xae (tedizolid phosphate) in the United States and certain of its territories.\n'

China Cefoperazone Sodium and Sulbactam Sodium Market Report 2021-2025: After the Implementation of the "4 + 7" Policy, Price May Decrease and Could Lead to Market Expansion

Retrieved on: 
Wednesday, April 21, 2021

b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.

Key Points: 
  • b'DUBLIN, April 21, 2021 /PRNewswire/ -- The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.
  • The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019.
  • In addition, after the implementation of the "4 + 7" policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.\nCefoperazone Sodium and Sulbactam Sodium is an injectable antibiotic.
  • Therefore, the analyst predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.\n2 Sales of Cefoperazone Sodium and Sulbactam Sodium in China, 2016-2020\n2.3 Sales of Cefoperazone Sodium and Sulbactam Sodium by Dosage Form in China, 2016-2020\n3 Analysis of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers in China, 2016-2020\n3.3 Zhendong Health Industry Group Co. Ltd.\n3.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.\n3.6 Shenzhen Lijian Pharmaceutical Co., Ltd.\n4 Prices of Cefoperazone Sodium and Sulbactam Sodium for Different Manufacturers in China, 2020-2021\n4.2 Zhendong Health Industry Group Co. Ltd. (Musitan)\n4.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Xinkuaixin)\n4.5 Shenzhen Lijian Pharmaceutical Co., Ltd. (Lijianshu)\n5 Prospect of Chinese Cefoperazone Sodium and Sulbactam Sodium Drug Market, 2021-2025\n'

Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Markets, 2016-2020 & 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 15, 2021

b'The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.

Key Points: 
  • b'The "Investigation Report on the Chinese Cefoperazone Sodium and Sulbactam Sodium Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nSales of the Cefoperazone Sodium and Sulbactam Sodium in China have an accelerated growth from 2017 to 2019.
  • The revenue in 2019 is approximately CNY 1.57 billion in 2020, though it dropped about 13.69% compared to 2019.
  • In addition, after the implementation of the "4 + 7" policy (a plan for the centralized procurement), the price of Cefoperazone Sodium and Sulbactam Sodium may decrease, which could lead the market to expand in the future.\nCefoperazone Sodium and Sulbactam Sodium is an injectable antibiotic.
  • Therefore, the analyst predicts that in the next few years, the sales volume of Cefoperazone Sodium and Sulbactam Sodium will rise as the market expands.\n2 Sales of Cefoperazone Sodium and Sulbactam Sodium in China, 2016-2020\n2.3 Sales of Cefoperazone Sodium and Sulbactam Sodium by Dosage Form in China, 2016-2020\n3 Analysis of Major Cefoperazone Sodium and Sulbactam Sodium Manufacturers in China, 2016-2020\n3.3 Zhendong Health Industry Group Co. Ltd.\n3.5 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd.\n3.6 Shenzhen Lijian Pharmaceutical Co., Ltd.\n4 Prices of Cefoperazone Sodium and Sulbactam Sodium for Different Manufacturers in China, 2020-2021\n4.2 Zhendong Health Industry Group Co. Ltd. (Musitan)\n4.4 Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. (Xinkuaixin)\n4.5 Shenzhen Lijian Pharmaceutical Co., Ltd. (Lijianshu)\n5 Prospect of Chinese Cefoperazone Sodium and Sulbactam Sodium Drug Market, 2021-2025\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005555/en/\n'

Atacand - Drug Insight Study 2019 with Worldwide Sales Forecasted to 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 4, 2019

The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Atacand- Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Atacand Drug Insight, 2019 highlights the drug marketed details and the Global API Manufacturers details across the globe along with the location.
  • The report covers the Global Market Assessment of the Atacand covering the historical global sales and also provides the Atacand sales estimation during the forecasted period (2019-2021).
  • In addition to this, the report also provides the SWOT analysis for Atacand and emerging therapies in this space.

Rosemarie Riddell Bogdan, Esq. Appointed to Plaintiffs' Steering Committee in National Valsartan NDMA Products Liability Litigation

Retrieved on: 
Wednesday, September 25, 2019

NISKAYUNA, N.Y., Sept. 25, 2019 /PRNewswire-PRWeb/ -- On May 6th, 2019, Martin, Harding & Mazzotti, LLP partner, RosemarieRiddell Bogdan , was appointed to a leadership position on the Plaintiffs' Personal Injury Steering Committee in the National Valsartan NDMA contamination litigation (IN RE: Valsartan Products Liability Litigation, MDL No.

Key Points: 
  • NISKAYUNA, N.Y., Sept. 25, 2019 /PRNewswire-PRWeb/ -- On May 6th, 2019, Martin, Harding & Mazzotti, LLP partner, RosemarieRiddell Bogdan , was appointed to a leadership position on the Plaintiffs' Personal Injury Steering Committee in the National Valsartan NDMA contamination litigation (IN RE: Valsartan Products Liability Litigation, MDL No.
  • The IN RE: Valsartan Products Liability Litigation, MDL No.
  • 2875centers around the FDA recalls of Valsartan which began in July of 2018 and have continued throughout 2019.
  • On February 14, 2019, the Judicial Panel on Multidistrict Litigation (JPML) issued a transfer order consolidating valsartan products liability lawsuits in the District of New Jersey.

Global and Chinese Market Valsartan Market Insights, 2014-2019 & 2019-2024 by Manufacturers, Product Type, Application, and Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 11, 2019

The "Valsartan Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Valsartan Market Insights 2019, Analysis and Forecast Global and Chinese Market to 2024, by Manufacturers, Product Type, Application, Regions and Technology" report has been added to ResearchAndMarkets.com's offering.
  • Valsartan Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Valsartan industry with a focus on the Chinese market.
  • Overall, the report provides an in-depth insight of 2014-2024 Global and Chinese Valsartan market covering all important parameters.
  • Through the statistical analysis, the report depicts the Global and Chinese total market of Valsartan industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply

Retrieved on: 
Thursday, April 25, 2019

The lots were sold exclusively to Golden State Medical Supply of Camarillo, California.

Key Points: 
  • The lots were sold exclusively to Golden State Medical Supply of Camarillo, California.
  • Golden State Medical Supply packages this bulk product under its own label and distributes in retail bottles of 30, 90, and 1000 tablets.
  • Teva promptly notified Golden State Medical Supply of the presence of the impurity in Heteros API and Teva will recall thirty-five (35) lots of bulk Losartan Potassium tablets sold to that company.
  • The tablets, which have been packaged and sold by Golden State Medical Supply, will be recalled from their customers and patients.

Information Update - Auro Pharma Inc. voluntarily recalls one lot of Auro-Irbesartan HCT tablets because of nitrosamine impurity

Retrieved on: 
Thursday, April 18, 2019

OTTAWA, April 18, 2019 /CNW/ -Health Canada is advising Canadians that Auro Pharma Inc. is voluntarily recalling one lot of Auro-Irbesartan/hydrochlorothiazide (HCT)combination tablets because of a nitrosamine impurity, N-nitrosodiethylamine (NDEA).

Key Points: 
  • OTTAWA, April 18, 2019 /CNW/ -Health Canada is advising Canadians that Auro Pharma Inc. is voluntarily recalling one lot of Auro-Irbesartan/hydrochlorothiazide (HCT)combination tablets because of a nitrosamine impurity, N-nitrosodiethylamine (NDEA).
  • NDEA is classified as a probable human carcinogen, which means that long-term exposure could increase the potential risk of cancer.
  • Auro Pharma Inc. is conducting the recall after Health Canada's testing identified levels of NDEA above what is considered reasonably safe if the drug were taken over a lifetime.
  • Health Canada maintains a complete list of sartan drugs that have been recalled because of nitrosamine impurities on its website .

FDA approves a new generic valsartan

Retrieved on: 
Tuesday, March 12, 2019

SILVER SPRING, Md., March 12, 2019 /PRNewswire/ --Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan).

Key Points: 
  • SILVER SPRING, Md., March 12, 2019 /PRNewswire/ --Today, the U.S. Food and Drug Administration approved a new generic of Diovan (valsartan).
  • The FDA prioritized the review of this drug application to help relieve the recent shortage of this critical medicine as a result of multiple recalls of generic valsartan products from several manufacturers due to the finding that certain lots of valsartan and other ARB medicines contain nitrosamine impurities.
  • "So to address the public health consequences of these shortages, we've prioritized the review of generic applications for these valsartan products.
  • Since last summer, the FDA has conducted a major investigation to address the presence of nitrosamine impurities in certain generic ARB products.